Current evidence on the use of the adalimumab biosimilar SB5 (ImraldiTM): a multidisciplinary perspective

Gisbert, Javier P., Gaffney, Karl, Young, David, Ebbers, Hans C. and Girolomoni, Giampiero (2022) Current evidence on the use of the adalimumab biosimilar SB5 (ImraldiTM): a multidisciplinary perspective. Expert Opinion on Biological Therapy, 22 (2). pp. 109-121. ISSN 1471-2598

[img]
Preview
PDF (14712598.2022) - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Preview

Abstract

Introduction: This review provides an overview of data from trials and real-world studies available for SB5 (ImraldiTM) across three main therapeutic areas: rheumatology, gastroenterology, and dermatology. Areas covered: A literature search for publications on data for SB5 efficacy/effectiveness, safety, and immunogenicity was undertaken. Expert opinion: Evidence derived from clinical studies suggest that the biosimilar SB5 is a safe and effective alternative to reference adalimumab. Considering that patients suffering from immune-mediated inflammatory diseases such as inflammatory arthritis, inflammatory bowel disease and psoriasis often require long-term biologic treatment, biosimilar medicines (such as SB5) can reduce healthcare costs while increasing access to effective treatments.

Item Type: Article
Additional Information: Funding Information: One of the peer reviewers of this manuscript declares to have received research grants from Pfizer, AbbVie and BMS. Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose. Funding Information: Dr Javier P. Gisbert has served as speaker, consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene, Gilead/Galapagos, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, and Vifor Pharma. Professor Karl Gaffney has received honoraria for attending advisory boards and delivering educational talks from Abbvie, Celltrion, Lilly, Novartis and UCB, and received research grants from Abbvie, Biogen, Novartis and UCB. Funding Information: Medical writing support was provided by Colin Gerard Egan, PhD (CE Medical Writing, SRLS, Pisa, Italy), and funding was provided by Biogen International GmbH, Switzerland. Publisher Copyright: © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Uncontrolled Keywords: adalimumab,anti-tnf,biosimilar,dermatology,gastroenterology,imraldi®,multidisciplinary,rheumatology,sb5,pharmacology,drug discovery,clinical biochemistry ,/dk/atira/pure/subjectarea/asjc/3000/3004
Faculty \ School:
Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 01 Mar 2022 16:30
Last Modified: 11 May 2022 00:44
URI: https://ueaeprints.uea.ac.uk/id/eprint/83812
DOI: 10.1080/14712598.2022.2012146

Actions (login required)

View Item View Item